Develop immunotherapies for cancer treatment. Advance allogeneic stem cell platforms for delivering anti-tumor payloads. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 12 months, company executives reported 23 buys and 1 sell. Management buying with its own money is usually read as a good sign.
A loss of $19.9M against $0 in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, CLDI sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CLDI is a high-risk stock — not yet profitable, and its future rides on its product catching on.
Not covered, because the filings we hold do not carry it: the revenue breakdown.